ELOX
Eloxx Pharmaceuticals, Inc. OTC$0.18
Mkt Cap $593,765
P/E (TTM)
-0.4x
EV/EBITDA
0.6x
P/B
—
Debt/Equity
-0.1x
ROE
50.3%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
-24.60
50d MA
$0.09
200d MA
$0.02
Avg Volume
6.7K
About
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The compan…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2023 | AMC | -1.97 | -1.31 | +33.5% | 1.18 | +0.8% | -6.8% | -6.8% | -2.5% | -2.5% | +1.7% | -42.4% | — |
| Aug 14, 2023 | AMC | -1.54 | -1.96 | -27.3% | 5.73 | -7.7% | -4.2% | -9.4% | -19.5% | -18.5% | -15.5% | -19.0% | — |
| May 15, 2023 | AMC | -2.55 | -2.88 | -12.9% | 10.90 | -27.2% | -23.7% | -15.7% | -17.7% | -18.4% | -19.7% | -36.0% | — |
| Apr 3, 2023 | AMC | -2.97 | -2.92 | +1.7% | 2.61 | +0.0% | +24.5% | +61.3% | +116.1% | +223.4% | +271.6% | +140.2% | — |
| Nov 10, 2022 | AMC | -4.40 | -3.60 | +18.2% | 4.40 | +9.1% | +0.0% | +18.2% | +27.3% | +18.2% | +27.3% | -36.1% | — |
| Aug 15, 2022 | AMC | -4.00 | -4.80 | -20.0% | 14.00 | +2.9% | +17.1% | +14.3% | +20.0% | +22.9% | +20.0% | +8.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 11 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.91 | $4.40 | +12.5% | +93.9% | +147.6% | +99.0% | +103.8% | +90.3% |
| Apr 6 | Oppenheimer | Maintains | Outperform → Outperform | — | $4.21 | $3.86 | -8.3% | +34.0% | +100.5% | +130.4% | +124.5% | +96.0% |
| May 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.60 | $13.60 | +0.0% | +0.0% | +0.0% | -2.9% | -8.8% | -11.8% |
| May 9 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.20 | $13.60 | +3.0% | -3.0% | -12.1% | -21.2% | -21.2% | -6.1% |
| Dec 17 | Oppenheimer | Maintains | Outperform → Outperform | — | $26.40 | $28.00 | +6.1% | +12.1% | +3.0% | +10.6% | +12.1% | +13.6% |
| Nov 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $34.80 | $30.80 | -11.5% | -11.5% | -21.8% | -24.1% | -24.1% | -13.8% |
| Nov 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $54.80 | $54.80 | +0.0% | -2.9% | -9.5% | -10.2% | -13.9% | -36.5% |
| Jun 30 | Mizuho | Maintains | Buy → Buy | — | $77.20 | $81.20 | +5.2% | +3.1% | +3.6% | +0.5% | +0.0% | -17.1% |
| May 27 | B. Riley Securities | Maintains | Buy → Buy | — | $56.40 | $59.20 | +5.0% | +5.7% | +10.6% | +14.9% | +12.8% | +36.2% |
| Jun 11 | Citigroup | Downgrade | Buy → Neutral | — | $137.00 | $128.00 | -6.6% | -13.1% | -13.1% | -10.9% | -8.8% | -10.9% |
Recent Filings
8-K
Eloxx Pharmaceuticals, Inc. -- 8-K Filing
Eloxx Pharmaceuticals is seeking shareholder approval through a Schedule 14C information statement for unspecified corporate actions, requiring a 20-day waiting period before implementation.
May 1
8-K
Unknown — 8-K Filing
Executive compensation arrangements for Hagen's appointment were disclosed under regulatory requirements, which investors should monitor for potential conflicts of interest or excessive pay packages affecting shareholder value.
Apr 10
Data updated apr 28, 2026 7:30am
· Source: massive.com